Biomarker, treatment patterns, and survival differences in metastatic triple-negative breast cancer by race in the United States.

Pegah Farrokhi, Leah Park, Howard Weston Schmutz, Samantha L Thompson, Clara Lam, Julian Bryan, David D Stenehjem

Abstract read

In one paragraph

Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pegah FarrokhiDepartment of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.

Leah ParkAstraZeneca, Gaithersburg, MD, USA.

Howard Weston SchmutzCollege of Pharmacy, University of Utah, Salt Lake City, UT, USA.

Samantha L ThompsonBiometrics Oncology, AstraZeneca, City House, Cambridge, UK.

Clara LamAstraZeneca, Gaithersburg, MD, USA.

Julian BryanMolecular Diagnostics Laboratory, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

David D StenehjemCollege of Pharmacy, University of Utah, Salt Lake City, UT, USA. stene032@d.umn.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) disproportionately affects Black women, with higher incidence rates and worse outcomes compared with White women. This study included 670 adult patients with metastatic TNBC diagnosed between January 2017 and March 2022 from the Flatiron Clinico-Genomic database. All patients underwent NGS-based testing and were assessed for prevalence of BRCA1/2, PIK3CA, AKT1, and PTEN alterations; treatment patterns; and survival outcomes. Of 670 patients, 28% were Black and 72% White. Black patients had higher BRCA1/2 alteration prevalence (12% vs. 7%; p < 0.04) but similar rates of other mutations. First-line therapy rates were comparable between groups. No significant differences in overall survival were observed (median 13.7 months for Black patients vs. 18.9 months for White patients; p = 0.15). Black patients with metastatic TNBC were nearly twice as likely to have BRCA1/2 alterations, suggesting potential benefit from PARP inhibition. Although survival differences were not statistically significant, larger studies are needed to understand racial disparities in treatments and outcomes.

Identifiers

PMID41951654

DOI10.1038/s41523-026-00945-w

PMCPMC13237146

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.